Ab+ cases, 2 groups were found; one included TNF- α , MCP-1 and IP-10, and the other had IFN- γ as a sole component.

Conclusion: Cytokine profiles differ among subgroups in myositis. In anti-DDA5+ myositis, IL-15 and IFN- α with strong correlation and IL-6 were characteristic cytokines, while IFN- γ was a unique one in anti-ARS+ myositis

Disclosure of Interests: None declared

DOI: 10.1136/annrheumdis-2019-eular.5542

SAT0282

EFFICACY AND SAFETY OF ORAL PROSTACYCLIN RECEPTOR AGONIST SELEXIPAG IN PATIENTS WITH SYSTEMIC SCLEROSIS -ASSOCIATED PULMONARY ARTERIAL HYPERTENSION IN DAILY CLINICAL PRACTICE, A CASE SERIES

Jacqueline Lemmers¹, Håvard Fretheim², Hanneke Knaapen-Hans¹, Frank van den Hoogen¹, Jolanda van Haren-Willems¹, Toon Duijnhouwer¹, C.H.M. van den Ende¹, Arie van Dijk¹, Anna-Maria Hoffmann-Vold², Madelon Vonk¹. ¹Radboud University Medical Centre, Nijmegen, Netherlands; ²Oslo University Hospital, Oslo, Norway

Background: Pulmonary arterial hypertension (PAH) is a frequent complication in systemic sclerosis (SSc) and a major cause of death despite the available treatments (1). Until the availability of the oral prostacyclin receptor agonist selexipag in 2016, parenteral medication targeting the prostacyclin pathway was often not feasible for patients with SSc-PAH due to practical barriers. Selexipag added to background therapy improves prognosis of PAH in the published pivotal trial (2). However, to date information on results of SSc-PAH patients treated with any combination of targeted therapies including selexipag in daily clinical practice are lacking.

Objectives: Evaluation of the efficacy and safety of selexipag in SSc-PAH patients in a real life case series.

Methods: All patients with SSc associated PAH (WHO group 1) diagnosed by right heart catheterization who started with selexipag between 09-2016 and 06-2018 from two PAH expert centres were included. Data on demographics, concurrent medication, functional class, 6 minute walking distance and NT-pro-BNP level were recorded at baseline and during follow-up. Every 12 weeks we recorded the opinion of the treating expert team, resulting in a conclusion "improvement", "stabilization" or "deterioration". Additionally treatment effect was assessed according to the abbreviated risk assessment described by Boucly (3). Side effects and adverse events were registered and evaluated.

Results: We included 13 SSc-PAH patients, all classified as limited cutaneous SSc. Ten patients were female. Median age was 68 years (IQR 58-75), median SSc disease duration 7.4 years (IQR 4.7-13.5) and median PAH duration 4 years (IQR 2.5-7.5). All patients were on double background therapy. At baseline 1 patient had two low risk criteria, 1 patient had one low risk criterion, the other patients had no low risk criteria. Two patients discontinued selexipag within 4 weeks due to side effects. The eleven patients reaching maintenance dosage had a median follow up of 48 weeks (IQR 24-72). At the end of follow up, 2/11 patients improved, 4/11 stabilized, and 5/11 deteriorated as evaluated by their expert team. Two of these deteriorated patients died due to right ventricular failure and gastro-intestinal bleeding respectively. Of the patients deteriorating, 3 initially stabilized for a period of 24 to 60 weeks. None of the patients achieved 3 low risk criteria, three patients achieved 1 low risk criterion. No unknown side effects were reported.

Conclusion: Adding selexipag to double background therapy in a high risk cohort stabilized symptoms in the majority of these patients with an acceptable safety profile. Sustained improvement of PAH symptoms is reached in only a minority of our SSc-PAH patients. Further research examining multiple target therapy, including selexipag, in patients with early SSc-associated PAH is warranted.

REFERENCES

- [1] Lefevre G, et al. Survival and prognostic factors in systemic sclerosis-associated pulmonary hypertension: a systematic review and meta-analysis. *Arthritis Rheum.* 2013;65(9):2412-23.
- [2] Sitbon O, et al. Selexipag for the Treatment of Pulmonary Arterial Hypertension. *N Engl J Med.* 2015;373(26):2522-33.
- [3] Boucly A, et al. Risk assessment, prognosis and guideline implementation in pulmonary arterial hypertension. *Eur Respir J.* 2017;50(2).

Disclosure of Interests: Jacqueline Lemmers: None declared, Håvard Fretheim Grant/research support from: Travel bursary from Actelion and GSK, Hanneke Knaapen-Hans: None declared, Frank van den Hoogen: None declared, Jolanda van Haren-Willems: None declared, Toon Duijnhouwer: None declared, C.H.M. van den Ende: None declared, Arie van Dijk Grant/research support from: Unrestricted grant for PhD student from Actelion, Consultant for: Actelion, Speakers bureau: Actelion, Anna-Maria Hoffmann-Vold Grant/research support from: Received research funding or other remuneration from Boehringer Ingelheim, GSK, and Actelion, Consultant for: Received consulting fees or other remuneration from Boehringer Ingelheim, GSK, and Actelion, Speakers bureau: Actelion and Boehringer Ingelheim, Madelon Vonk Grant/research support from: Madelon Vonk has received unrestricted research funds from Actelion and Therabel, Consultant for: Madelon Vonk was a consultant for Actelion, Boehringer-Ingelheim, Speakers bureau: Actelion, Boehringer-Ingelheim, Roche

DOI: 10.1136/annrheumdis-2019-eular.3021

SAT0283

CLINICAL AND SEROLOGICAL FEATURES OF SYSTEMIC SCLEROSIS IN ITALIAN AND EGYPTIAN PATIENTS

Vasiliki Liakouli¹, Hesham Hamoud², Piero Ruscitti¹, Mahmoud Ibrahim Risha³, Mohamed Elsayed Hanafy³, Khaled Elnaafy³, Rasha Ali⁴, Gihan Omar⁴, Adel Elsayed⁵, Abdelazeim Elhefny⁵, Mervat Abogabal⁵, Sameh Mobasher⁵, Paola Cipriani¹, Roberto Giacomelli¹. ¹University of L'Aquila, L'Aquila, Italy; ²University of Al Azhar, Cairo, Egypt; ³Al Azhar University, Cairo, Egypt; ⁴Minia University, Cairo, Egypt; ⁵Ain Shams University, Cairo, Egypt

Background: Clinical and serological variations exist in the severity of Systemic Sclerosis (SSc) patients, according to different geographic areas.

Objectives: To evaluate clinical and serological features in 2 cohorts of Italian and Egyptian SSc patients and to identify factors associated with Interstitial lung disease (ILD), a leading cause of mortality, by using multivariate logistic regression analysis.

Methods: An Italian center and 3 Egyptian centers participated in SSc patient recruitment in 2017. The cross-sectional demographic, clinical, and laboratory data were collected and defined according to severity score and activity index, previously developed [1, 2]. The database included 152 consecutive Italian patients, 135 women (88.8%) and 17 men (11.2%) and 197 consecutive Egyptian SSc patients, 177 women (89.8%) and 20 men (10.2%), all of whom fulfilled the classification criteria proposed by LeRoy and Medsger [3].

Results: We found that Egyptians SSc patients were younger (41.18±12.5 vs 58.59±12.6 yrs), had an earlier onset of the first non Raynaud's Phenomenon symptom (7.28±5.89 vs 14.99±11.11) and a more severe Modified Rodnan Skin Score (MRSS>14) (79.27% vs 13.6%). A greater percentage of Egyptian patients presented the active form of the disease (53.3% vs 15.5%) and had a Pulmonary Arterial Pressure (PAPs) estimated by echocardiography ≥ 40 mmHg (37.5% vs 10.6%), than Italian patients. Furthermore, Egyptian patients affected from the limited form of the disease (lcSSc), presented a higher MRSS (67.2% vs 2.6%), higher PAPs levels (34.5% vs 9.2%), an active form (41.7% vs 7.8%) and history of past/current ulcers (62.2% vs 30.6%) than Italian lcSSc patients. Severity score was higher in Egyptian patients than in the Italians (General: 22.9% vs 6.2%, Peripheral vascular: 48.2% vs 23.9%, skin: 19.8% vs 3.6%, joint/tendon: 19.9% vs 8.5%, muscle: 8.1% vs 2.6%, lung: 41.1% vs 25.3%, heart: 11.2% vs 4.1%). Kidney involvement was more severe in the diffuse cutaneous form (dcSSc) of the disease in Egyptians patients than Italians (2% vs 0.4%). In the multivariate analysis, PAPs ≥ 40 mmHg (OR: 2.622, 95%CI:1.031-6.660, p=0.043), past/current ulcers (OR:3.450, 95%CI:1.265-9.409, p=0.016), presence of anticentromere (ACA) (OR:3.846, 95%CI:1.488-9.940, p=0.005) and anti-topoisomerase I (SCL70) (OR:5.012, 95%CI:1.740-14.441, p=0.003) antibodies and heart involvement (OR:3.018, 95%CI:1.448-6.288, p=0.003) were associated with ILD in the Egyptian database, suggesting a potential role as predictive biomarkers. Advanced age (OR:1.036, 95%CI:1.009-1.063, p=0.008), dcSSc (OR:4.726, 95%CI:2.021-11.049, p=0.001) and joint involvement (OR:1.695, 95%CI:1.094-2.627, p=0.018) were independently associated with ILD in the Italian patients.

Conclusion: This cross-sectional study analyzed the demographic, clinical and laboratoristic variations in Egyptians and Italian patients and their association with ILD, suggesting possible differences to be further investigated in adequately powered studies.